BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35587529)

  • 1. Pan-TRK Immunohistochemistry and NTRK Gene Fusions in Primary Carcinomas of the Liver.
    Zhang D; Liao X
    Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):435-440. PubMed ID: 35587529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
    Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
    Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
    Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
    Sholl LM; Zheng M; Nardi V; Hornick JL
    Histopathology; 2021 Aug; 79(2):260-264. PubMed ID: 33682174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
    Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
    Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
    Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
    Moura MS; Costa J; Velasco V; Kommoss F; Oliva E; Le Loarer F; McCluggage WG; Razack R; Treilleux I; Mills A; Longacre T; Devouassoux-Shisheboran M; Hostein I; Azmani R; Blanchard L; Hartog C; Soubeyran I; Khalifa E; Croce S
    Histopathology; 2024 Feb; 84(3):451-462. PubMed ID: 37988282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
    Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
    Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
    Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
    Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
    Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
    Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma.
    Strohmeier S; Brcic I; Popper H; Liegl-Atzwanger B; Lindenmann J; Brcic L
    Sci Rep; 2021 May; 11(1):9785. PubMed ID: 33963267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of
    Koopman B; Kuijpers CCHJ; Groen HJM; Timens W; Schuuring E; Willems SM; van Kempen LC
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.